Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals reviews accounting for its Philidor arrangement
Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In light of the recent allegations made regarding Philidor,
Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In light of the recent allegations made regarding Philidor,
The AAC reviewed safety and efficacy data from the pivotal Phase III combination therapy programme trials, representing the largest clinical trial data set of gout patients treated with
The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the
Professor David E. Thurston of the Institute of Pharmaceutical Science will lead a team at King’s to develop and optimize a range of specific small molecules for Auris
Strensiq, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare
The expansion of the plant became necessary to make room for research and development, quality management, laboratory, production and logistics. 2,250 square meters of clean room space, certified
In total, the actions are expected to add incremental benefits of $175m when the full run rate of the plan is achieved. With the inclusion of approximately $0.153
It also announces it has been awarded over 20 products in response to a tender from the Department of Health for a new supply of medicines to maintain
In March 2015, RedHill Biopharma acquired from Apogee the exclusive worldwide rights to YELIVA (ABC294640), a first-in-class, orally-administered sphingosine kinase-2 ("SK2") selective inhibitor. Following prior pre-clinical studies in
GDC-0310 is a selective, oral Nav1.7 small-molecule inhibitor, identified as part of the companies’ pain collaboration focused on the Nav1.7 target. Genentech has initiated a Phase 1 clinical